Effect of selective phosphodiesterase inhibitors on response of ovine pulmonary arteries to prostaglandin E2

Journal of Applied Physiology

Volumn 84, Issue 1, 1998, Pages 13-18

  Gao, Yuansheng ^a,b   Tolsa, Jean François ^a   Shen, Hai ^a   Raj, J Usha ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Forskolin; Milrinone; Perinatal pulmonary circulation; Rolipram

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; ACETYLCHOLINE; CYCLIC AMP; CYCLIC GMP; FORSKOLIN; MILRINONE; N(G) NITROARGININE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E2; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; LAMB; LUNG ARTERY; LUNG CIRCULATION; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0031934250     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1998.84.1.13     Document Type: Article

References (37)

1. Barnes, P. J., and S. F. Liu. Regulation of pulmonary vascular tone. Pharmacol. Rev. 47: 87-131, 1995.
2. Beavo, J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Pharmacol. Rev. 75: 725-748, 1995.
3. Beavo, J. A., and D. H. Reifsnyder. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11: 150-155, 1990.
4. Bradford, M. M. A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Chem. 72: 249-254, 1973.
5. Cassin, S. Role of prostaglandins and thromboxanes in the control of the pulmonary circulation in the fetus and newborn. Semin. Perinatol. 4: 101-107, 1980.
6. Chang, A. C., A. M. Atz, G. Wernovsky, R. P. Burke, and D. L. Wessel. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit. Care Med. 23: 1907-1914, 1995.
7. Clarke, W. R., S. Uezono, A. Chambers, and P. Doepfner. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol. 7: 81-89, 1994.
8. Coleman, R. A., W. L. Smith, and S. Narumiya. VIII International Union of Pharmacology classification of prostanoid receptor: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46: 205-229, 1994.
9. Cornfield, D. N., B. A. Chatfield, J. A. McQueston, I. F. McMurtry, and S. H. Abman. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am. J. Physiol. 262 (Heart Circ. Physiol. 31): H1474-H1481, 1992.
10. Dent, G., H. Magnussen, and K. F. Rabe. Cyclic nucleotide phosphodiesterases in the human lung. Lung 172: 129-146, 1994.
11. Eckly, A. E., and C. Lugnier. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113: 445-450, 1994.
12. Fineman, J. R., S. J. Soifer, and M. A. Heymann. Regulation of pulmonary vascular tone in the perinatal period. Annu. Rev. Physiol. 57: 115-134, 1995.
13. 2 cause greater relaxations in pulmonary veins than in arteries of newborn lambs. J. Appl. Physiol. 81: 2534-2539, 1996.
14. Gao, Y., H. Zhou, and J. U. Raj. Endothelium-derived nitric oxide plays a larger role in pulmonary veins than in arteries of newborn lambs. Circ. Res. 76: 559-565, 1995.
15. Givertz, M. M., J. M. Hare, E. Loh, D. F. Gauthier, and W. S. Colucci. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J. Am. Coll. Cardiol. 28: 1775-1780, 1996.
16. Grace, G. C., P. S. Macdonald, and G. J. Dusting. Cyclic nucleotide interactions involved in endothelium-dependent dilation in rat aortic rings. Eur. J. Pharmacol. 148: 17-24, 1988.
17. 2+ transients. Circ. Res. 69: 1369-1379, 1991.
18. Ignarro, L. J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 30: 535-560, 1990.
19. 2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. USA 93: 295-299, 1996.
20. Lincoln, T. M., and V. Fisher-Simpson. A comparison of the effects of forskolin and sodium nitroprusside on cyclic nucleotides and relaxation in the rat aorta. Eur. J. Pharmacol. 101: 17-27, 1984.
21. Lugnier, C., P. Schoeffter, A. Le Bee, E. Strouthou, and J. C. Stoclet. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35: 1743-1751, 1986.
22. Martinez, A. M., J. F. Padbury, J. A. Humme, C. W. Evan, and L. Shames. Plasma catecholamine and their physiological thresholds during the first ten days of life in sheep. J. Dev. Physiol. (Eynsham) 13: 141-146, 1990.
23. Maurice, D. H., D. Crankshaw, and R. J. Haslam. Synergistic action of nitrovasodilators and isoproterenaline on rat aortic smooth muscle. Eur. J. Pharmacol. 192: 235-242, 1991.
24. Moncada, S., R. M. J. Palmer, and E. A. Higgs. Nitric oxide: physiology, pathology, and pharmacology. Pharmacol. Rev. 43: 109-142, 1991.
25. Morita, T., M. Ando, K. Kihara, H. Oshima, S. Kondo, and Y. Tashima. Dissociation of magnitude of relaxation from cyclic AMP levels in rabbit urinary bladder smooth muscles. J. Smooth Muscle Res. 28: 121-128, 1992.
26. 5-[imino-(nitroamino)methyl]-L-ornithine) impairs endothelium-dependent dilations by inhibiting cytosolic nitric oxide synthesis from L-arginine. Naunyn Schmiedebergs Arch. Pharmacol. 341: 143-147, 1990.
27. Noel, P. E., J. R. Fletcher, and W. J. Thompson. Rolipram and isoproterenol reverse platelet activating factor-induced increases in pulmonary microvascular permeability and vascular resistance. J. Surg. Res. 59: 159-164, 1995.
28. Ono, S., S. Ueda, T. Sakuma, T. Tanita, K. Koika, and S. Fujimura. Relaxation of human isolated pulmonary arteries by amrinone. J. Cardiovasc. Surg. (Torino) 37: 177-181, 1996.
29. Polson, J. B., and S. J. Strada. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36: 403-427, 1996.
30. Rabe, K. F., H. Tenor, G. Dent, C. Schudt, M. Nakashima, and H. Magnussen. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266 (Lung Cell. Mol. Physiol. 10): L536-L543, 1994.
31. Rapundalo, S. T., R. J. Solaro, and E. G. Kranias. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ. Res. 64: 104-111, 1989.
32. Reeves, M. L., and P. J. England. Cardiac phosphodiesterases and the functional effects of selective inhibition. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edited by J. Beavo and M. D. Houslay. New York: Wiley, 1990, p. 299-332.
33. Shaul, P. W., W. B. Campbell, M. A. Farrar, and R. R. Magness. Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J. Clin. Invest. 90: 2147-2155, 1992.
34. Sheppard, H., and G. A. T. W. Wiggan. Structure-activity relationships for inhibitors of phosphodiesterases from erythrocyte and other tissues. Adv. Cyclic Nucleotide Res. 1: 103-112, 1996.
35. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J. Pharmacol. Exp. Ther. 247: 34-42, 1988.
36. Wells, J. N., and J. R. Miller. Methylxanthine inhibitors of phosphodiesterases. Methods Enzymol. 159: 489-496, 1988.
37. Zhou, H. L., S. J. Newsholme, and T. J. Torphy. Agonist-related differences in the relationship between cAMP content and protein kinase activity in canine trachealis. J. Pharmacol. Exp. Ther. 261: 1260-1267, 1992.